Skip to main content
. 2021 Feb 18;22(4):2025. doi: 10.3390/ijms22042025

Figure 5.

Figure 5

Tumor immunity was markedly enhanced by depletion of regulatory T cells (Tregs) in CCL17 transgenic (TG) mice. (A) Phenotypical manifestation of back skin from wild-type (WT) and CCL17 TG mice treated with anti-CD25 Ab or phosphate-buffered saline (PBS) peritoneally 14 days after injection of B16F1 cells subcutaneously. (B) Schema describing strategy for Tregs depletion with anti-CD25 Ab. Anti-CD25 Ab was injected peritoneally two days before subcutaneous inoculation of B16F1 cells and tumor sizes were evaluated on days 3, 7, 10, and 14. (C) Tumor size was dramatically decreased in CCL17 TG mice treated with anti-CD25 Ab compared with that in WT treated with anti-CD25 Ab and that in CCL17 TG mice treated with PBS. * p < 0.05, ** p < 0.01.